Dark Blue Therapeutics

Some of the most aggressive cancers, such as acute myeloid leukaemia (AML), depend on molecular ‘Achilles’ heels’ – critical weaknesses that can be targeted, if they’re found.

Dark Blue Therapeutics is developing precision oncology therapies that exploit these cancer-specific vulnerabilities. By combining cutting-edge academic research with deep industry expertise, the company is advancing a new generation of treatments designed to outsmart the toughest cancers.